Aker BioMarine announced the appointment of biotechnology and pharmaceutical executive Douglas C. Hicks to the position of Senior Vice President – Business Development and Strategy, to lead the company's entry into the pharmaceutical segment. Based out of the U.S., Mr. Hicks will play an integral role in the development of new product segments for the company's LYSOVETA™, a new krill-based LPC-EPA/DHA delivery platform. He will develop and drive LYSOVETA's growth outside of the company's core supplement segment, with a focus on pharmaceutical and medical food applications. Mr. Hicks comes to the company with over 20 years of experience in corporate development and business strategy execution within the biotechnology, pharmaceutical and venture capital segments. He most recently served as Chief Business Officer for Travecta Therapeutics Inc. where he led and executed multiple collaborations for the company. Prior to Travecta, Mr. Hicks served as Senior Vice President of Business Development and Strategy at iBio Inc., where he was responsible for leading the business development and strategic initiatives of the company. He began his career at Bristol-Myers Squibb and Clearview Projects Inc. and holds a Master of Business Administration with a focus on finance and strategy from Pennsylvania State University.